Table 3.

Saxagliptin glucose effects in monotherapy and combination therapy for type 2 diabetes.

Design	N	Treatment and dose	Study duration (weeks)	Baseline HbA1c	Outcome				Reference
					Adjusted mean change from baseline HbA1c (%)	Patients (%) reaching HbA1c, <7.0%	Adjusted mean change from baseline FPG (mmol/L)	Adjusted mean change from baseline PPG-AUC(mmol*min/L)
Monotherapy	106	SAXA 5 mg	24	8.0	−0.5a	38a	−0.50a	−383a	Rosenstock, 2009
	95	PBO		7.9	0.2	24	0.33	−36
Monotherapy	74	SAXA 5 mg QAM	24	7.9	−0.7a	45	−0.61	−456	CV181038
	72	SAXA 5 mg QPM		7.9	−0.6a	39	−0.44	−336
	74	PBO		7.8	−0.3	35	0.17	−171
With MET	191	SAXA 5 mg + MET	24	8.1	−0.7a	44a	−1.22	−532a	DeFronzo, 2009
	179	PBO + MET		8.1	0.1	17	0.07	−183
With SU	253	SAXA 5 mg + GLY	24	8.5	−0.6a	23a	−0.56a	−278a	Chacra, 2009
	267	PBO + UP-GLY		8.4	0.08	9	0.06	66
With TZD	186	SAXA 5 mg + TZD	24	8.4	−0.9a	42	−1.00	−514a	Hollander, 2009
	184	PBO + TZD		8.2	−0.3	26	−0.20	−149
Initial combination with MET	320	SAXA 5 mg + MET	24	9.4	−2.5a	60a	−3.33a	1170a	Jadzinsky, 2009
	328	PBO + MET		9.4	−2.0	41	−2.61	−823
Long-term with METb	191	SAXA 5 mg + MET	102	8.1	−0.40	30	−0.63	−323a	DeFronzo, 2009
	179	PBO + MET		8.1	−0.32	12	0.38	−64
Long-term with SUb	253	SAXA 5 mg + GLY	76	8.5	0.03	10	0.44	−122	Clinicalstudyresults.org 2009
	267	PBO + UP-GLY		8.4	0.69	5	0.23	181

Reprinted from Core Evidence, 5, Kalusa et Edelman, Saxagliptin: The evidence for its place in the treatment of type 2 diabetes mellitus, 23–37, 201, with permission from Dove Medical Press Ltd.⁵⁶